While it is fair to say the biotech sector has started to feel the effects of a softening of investor risk appetite, the muted investor appetite for biotech is also perhaps due to the sector entering something of a transitional phase.
The larger commercial-stage companies that led the sector's strong performance over the past few years have matured to resemble their slower-growing pharmaceutical peers. In contrast, investor enthusiasm...
'This is not going to end well': Buyers warn bonds will not be safe haven of the past in next market correction
Concern over impact QE ending and low yields
Explaining the strength of the dollar
26 years in financial services
Latest news and analysis